Sartan concerns are expanding in the U.S. after N-nitrosodiethylamine (NDEA), a potential carcinogen, was found in some lots of Hauppauge, N.Y.-based Sciegen Pharmaceuticals Inc.'s irbesartan tablets, which contain API from Aurobindo Pharma Ltd., of Hyderabad, India. Lots of the finished hypertension drug and API that may contain the impurity are being recalled from the U.S. market.